ELV reaffirms 2026 EPS guidance; targets 12%+ 2027 growth
Management reaffirmed 2026 EPS guidance and expects at least 12% EPS growth in 2027. The company attributes the outlook to execution, favorable cost trends, disciplined investments in AI and Carelon, and strong performance across Medicare Advantage, Medicaid, and ACA segments.
Management reaffirmed 2026 EPS guidance and said it expects at least 12% EPS growth in 2027, supported by strong execution, favorable cost trends, and disciplined investments in AI and Carelon. The company said Medicare Advantage, Medicaid, and ACA are all running ahead of expectations, with an improved rate environment.